Evolus Inc Revenue Growth Rates (EOLS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Evolus Inc   (NASDAQ: EOLS)
 

EOLS's Revenue Growth by Quarter and Year

Evolus Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/EOLS/growth
https://api.csimarket.com/api/v1/companies/EOLS/fundamentals
https://api.csimarket.com/api/v1/companies/EOLS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
EOLS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 77.95
2nd Quarter June 84.08
1st Quarter March 72.90
FY 234.93

EOLSs Annual Revenue
Evolus Inc 's Revenue in the fiscal year 2025 $ 297.11 millions
Evolus Inc 's Revenue in the fiscal year 2024 $ 184.30 millions
Evolus Inc 's Revenue in the fiscal year 2023 $ 202.09 millions
Evolus Inc 's Revenue in the fiscal year 2022 $ 148.62 millions
Evolus Inc 's Revenue in the fiscal year 2021 $ 99.67 millions




EOLS Revenue third quarter 2026 Y/Y Growth Comment
Evolus Inc reported Revenue increase of 13.24% year on year in the third quarter 2026, to $ 77.95 millions, this is lower than Evolus Inc 's recent average Revenue rise of 50.72%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 83 other companies have achieved higher Revenue growth. While Evolus Inc ' s Revenue growth of 13.24% ranks overall at the positon no. 1004 in the third quarter 2026.


EOLS Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 13.24 %
2nd Quarter June 21.29 %
1st Quarter March 7.74 %
FY   -

Financial Statements
Evolus Inc 's third quarter 2026 Revenue $ 77.95 millions EOLS's Income Statement
Evolus Inc 's third quarter 2025 Revenue $ 68.84 millions Quarterly EOLS's Income Statement


EOLS Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -7.29 %
2nd Quarter June 15.34 %
1st Quarter March -20.14 %
FY (Year on Year)   -


Back to EOLS Growth rate Comparisons >> Back to EOLS Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #84
Healthcare Sector #199
Overall #1004

Revenue Y/Y Growth Statistics
High Average Low
237.78 % 50.72 % 3.6 %
(Mar 31 2022)   (Mar 31 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #84
Healthcare Sector #199
Overall #1004
Revenue Y/Y Growth Statistics
High Average Low
237.78 % 50.72 % 3.6 %
(Mar 31 2022)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Evolus Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
469.75 % 28.71 % -46.03 %
(Sep 30 2019)  


EOLS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Evolus Inc disclosed drop in Revenue from the second quarter by -7.29% to $ 77.95 millions, from $ 84.08 millions achived in the previous reporting period.

But that's not important problem, as Evolus Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Evolus Inc 's Revenue growth quarter on quarter, overall rank is 638.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #114
Overall #638
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #114
Overall #638
Revenue Q/Q Growth Statistics
High Average Low
469.75 % 28.71 % -46.03 %
(Sep 30 2019)  


EOLS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Evolus Inc disclosed drop in Revenue from the second quarter by -7.29% to $ 77.95 millions, from $ 84.08 millions achived in the previous reporting period.

But that's not important problem, as Evolus Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Evolus Inc 's Revenue growth quarter on quarter, overall rank is 638.


Evolus Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 317.11
Y / Y Revenue Growth (TTM) 14.48 %
Year on Year Revenue Growth Overall Ranking # 1012
Seqeuential Revenue Change (TTM) 4.88 %
Seq. Revenue Growth (TTM) Overall Ranking # 2538


Cumulative Revenue growth Comment
Although Evolus Inc 's Annual Revenue growth year on year were below company's average 39.42% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 14.48% year on year, from 10.11% in Mar 31 2026.

In the Healthcare sector 193 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 172 to 1012.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 194
Overall # 1012

Revenue TTM Y/Y Growth Statistics
High Average Low
108.18 %
 39.42 %
10.11 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 368
S&P 500 # 2538
Cumulative Revenue growth Comment
Although Evolus Inc 's Annual Revenue growth year on year were below company's average 39.42% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 14.48% year on year, from 10.11% in Mar 31 2026.

In the Healthcare sector 193 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 172 to 1012.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 194
Overall # 1012

Revenue TTM Y/Y Growth Statistics
High Average Low
108.18 %
39.42 %
10.11 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 368
S&P 500 # 2538




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EOLS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Protalix Biotherapeutics inc 22.82%$ 22.822 millions
Atrium Therapeutics Inc 22.81%$ 22.814 millions
Capsovision Inc 22.44%$ 22.443 millions
Veracyte Inc 22.10%$ 22.105 millions
Radnet Inc 22.07%$ 22.068 millions
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Anteris Technologies Global Corp 20.98%$ 20.979 millions
Trisalus Life Sciences Inc 20.81%$ 20.807 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Alpha Pro Tech Ltd 19.73%$ 19.729 millions
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions


About Evolus Inc Revenue Growth Rates (EOLS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Evolus Inc (CIK 1570562).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-070250
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Evolus Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.